Seaport Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Seaport Therapeutics, Inc. (SPTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 34.4% of the shares are freely tradable; institutional investors hold 43.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARCH VENTURE CORP | 11.76 | 6,294,951 | +0.0 | 06/30/2026 |
| General Atlantic Llc | 11.40 | 6,101,582 | +0.0 | 06/30/2026 |
| Sofinnova Ventures | 6.66 | 3,564,871 | +0.0 | 06/30/2026 |
| The Goldman Sachs Group Inc | 4.07 | 2,178,642 | +0.0 | 06/30/2026 |
| TRV GP VI, LLC | 3.85 | 2,061,222 | +0.0 | 06/30/2026 |
| Canada Pension Plan Investment Board | 3.69 | 1,975,791 | +0.0 | 06/30/2026 |
| JPMorgan Chase & Co | 3.39 | 1,815,845 | +0.0 | 06/30/2026 |
| Foresite Capital Management VI LLC | 3.32 | 1,779,521 | +0.0 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 2.44 | 1,308,604 | +0.0 | 06/30/2026 |
| FMR Inc | 2.21 | 1,185,100 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Zohar Daphne | Chief Executive Officer | 1,094,001 | 20,895,419 $ | Nov 10, 2026 | direct |
| Torres Denice | Director | 5,000 | 95,500 $ | Nov 3, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Zohar Daphne | Chief Executive Officer | Other | 100,000 | 0.00 | – |
| Nov 3, 2026 | Torres Denice | Director | Buy | 5,000 | 19.87 | 99,325 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 16, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.